Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;22(3):e070122200096.
doi: 10.2174/1871526522666220107125511.

Therapeutic Status of Famotidine in COVID-19 Patients: A Review

Moein Mohseni  1 , Vahid Raissi  2 , Yasamin Sharifan  3 , Kimia Barikro  1 , Sasan Amiri  4 , Maedeh Sadat Mohseni  5 , Farid Raeisi  6 , Kimia Masoumi  1 , Sina Khodakarami  1 , Omid Raiesi  7
Affiliations
Review

Therapeutic Status of Famotidine in COVID-19 Patients: A Review

Moein Mohseni et al. Infect Disord Drug Targets. 2022.

Abstract

The novel coronavirus, SARS-coV-2, which emerged in Wuhan in November 2019, has increasingly spread worldwide. More than 272 million cases of infection have been identified. COVID-19 has affected 223 countries and territories across the world. The principal target of the SARS-CoV-2 infection is the lower respiratory tract. Series of moderate to non-specific severe clinical signs and symptoms appear two to fourteen days after exposure to SARS-CoV-2 in patients with COVID-19 disease, including cough, breath deficiency, and at least two of these symptoms: headache, fever, chills, repeated rigor, myalgia, oropharyngitis, anosmia, and ageusia. No therapeutic agents have been validated to have substantial efficacy in the clinical care of COVID-19 patients in large-scale trials, despite worsening infected rates of COVID-19. Early clinical evidence from many sources suggests that treatment with famotidine may decrease COVID-19-related morbidity and mortality. The mechanism by which famotidine could improve the outcomes of COVID-19 is currently unknown. A more recent postulated mechanism is that the effect of famotidine is mediated by histamine-2 receptor antagonism or inverse agonism, inferring that the SARS-CoV-2, resulting in COVID-19 infection, at least partially leads to the abnormal release of histamine and perhaps dysfunction of mast cells.

Keywords: COVID-19; SARS-coV-2; famotidine; histamine-2 receptor antagonism; respiratory syndrome disease; therapeutic.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

LinkOut - more resources